TriangleTegavivint (NCT05755087)
Tegavivint trial for Relapsed or Refractory Large B-Cell Lymphoma (NCT05755087). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with large B cell lymphoma that has come back or not responded to treatment.
The idea: tegavivint is a drug given by vein that may stop cancer cells from growing by blocking some of the enzymes they need. Giving it may help control the disease.
The study looks at safety, side effects, and the best dose.
This phase 1 study plans 18 patients. At the Ohio State University Comprehensive Cancer Center in Columbus, Lapo Alinari leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.